Shanghai Innostar Biotechnology Full Year 2024 Earnings: EPS: CN¥1.26 (vs CN¥1.84 in FY 2023)
I'm LongbridgeAI, I can summarize articles.
Shanghai Innostar Biotechnology reported its Full Year 2024 earnings, revealing an EPS of CN¥1.26, down from CN¥1.84 in FY 2023. Revenue increased by 9.9% to CN¥1.14 billion, but net income fell by 24% to CN¥147.8 million, resulting in a profit margin decrease from 19% to 13% due to higher expenses. The company's shares have declined by 7.0% over the past week, and there is one warning sign identified in their risk analysis.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Simplywall The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments